Daiichi Sankyo exon-skips into ultra-orphan ring with DMD alliance
This article was originally published in Scrip
Executive Summary
Perhaps encouraged by strong global investor and clinician interest in companies developing new drugs for very rare orphan diseases, Daiichi Sankyo has unveiled plans for a new Japanese joint venture specializing in antisense oligonucleotides for the treatment of Duchenne muscular dystrophy (DMD).